|
FR104E
(https=)
|
|
|
|
|
|
US5843708A
(en)
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DE19939653A1
(de)
|
1999-08-13 |
2001-02-22 |
Thomas Huenig |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
ATE363290T1
(de)
|
1999-10-04 |
2007-06-15 |
Novartis Vaccines & Diagnostic |
Cd40 antagonist zur behandlung von psoriasis
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
WO2002011763A1
(en)
|
2000-04-19 |
2002-02-14 |
Tanox, Inc. |
Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
EP1322383B9
(en)
|
2000-10-02 |
2006-09-06 |
Chiron Corporation |
Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
WO2003075846A2
(en)
|
2002-03-08 |
2003-09-18 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8h9
|
|
US8501471B2
(en)
|
2000-10-18 |
2013-08-06 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
US20020102264A1
(en)
|
2000-10-18 |
2002-08-01 |
Cheung Nai-Kong V. |
Uses of monoclonal antibody 8H9
|
|
EP1399187A4
(en)
|
2000-10-18 |
2005-09-21 |
Sloan Kettering Inst Cancer |
APPLICATIONS OF MONOCLONAL ANTIBODY 8H9
|
|
US8414892B2
(en)
|
2000-10-18 |
2013-04-09 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
KR20040020866A
(ko)
|
2000-12-14 |
2004-03-09 |
후지사와 야꾸힝 고교 가부시키가이샤 |
사일런스 항-ｃｄ28 항체 및 그의 용도
|
|
DK1345969T3
(da)
|
2000-12-26 |
2010-11-29 |
Inst Nat Sante Rech Med |
Anti-CD28-antistof
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
CA2658221C
(en)
|
2001-04-27 |
2012-11-27 |
Kyowa Kirin Co., Ltd. |
Anti-cd40 monoclonal antibody
|
|
WO2003029296A1
(en)
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Human anti-cd40 antibodies
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
AU2002346581A1
(en)
|
2001-11-26 |
2003-06-10 |
Chiron Corporation |
Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
US7052694B2
(en)
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
US6693136B1
(en)
|
2002-07-26 |
2004-02-17 |
Abbott Laboratories |
Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
|
|
JP2006500921A
(ja)
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト４−１ｂｂに対するヒト化抗体
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
|
US7618632B2
(en)
|
2003-05-23 |
2009-11-17 |
Wyeth |
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
|
|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
EP1600164A3
(de)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
KR101128777B1
(ko)
|
2003-11-04 |
2012-04-13 |
조마 테크놀로지 리미티드 |
다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
|
|
WO2005044307A2
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Methods of therapy for b cell-related cancers
|
|
PL1680141T3
(pl)
|
2003-11-04 |
2011-04-29 |
Novartis Vaccines & Diagnostics Inc |
Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
|
|
SI1682177T1
(sl)
|
2003-11-04 |
2010-12-31 |
Novartis Vaccines & Diagnostic |
Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
|
|
ATE447412T1
(de)
|
2003-11-04 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
CN1922316B
(zh)
|
2003-12-25 |
2011-03-23 |
协和发酵麒麟株式会社 |
抗cd40抗体突变体
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
AU2005259221B2
(en)
|
2004-07-01 |
2011-02-10 |
Innate Pharma |
Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
|
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
SI1835937T1
(sl)
|
2005-01-06 |
2012-08-31 |
Novo Nordisk As |
Sestavki in postopki za zdravljenje virusne infekcije
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
CN101103043A
(zh)
|
2005-01-06 |
2008-01-09 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
US20070161644A1
(en)
|
2005-01-25 |
2007-07-12 |
Stockwell Brent R |
Erastin analogs and uses thereof
|
|
JP5139083B2
(ja)
|
2005-01-25 |
2013-02-06 |
プロレキシーズ ファーマシューティカルズ インコーポレイテッド |
抗腫瘍剤としてのキノキサリン誘導体
|
|
US8323645B2
(en)
|
2005-03-24 |
2012-12-04 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
US20060240006A1
(en)
|
2005-04-20 |
2006-10-26 |
Chishih Chu |
Novel antibody structures derived from human germline sequences
|
|
AU2006239318A1
(en)
|
2005-04-27 |
2006-11-02 |
Cs-Keys, Inc |
Cancer specific PCNA isoform binding antibodies and uses thereof
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
US7585960B2
(en)
|
2005-05-11 |
2009-09-08 |
Theramab Gmbh |
Nucleic acids encoding superagonistic anti-CD28 antibodies
|
|
JP5421590B2
(ja)
|
2005-05-18 |
2014-02-19 |
ノバルティス アーゲー |
自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
|
|
AU2006247067B2
(en)
|
2005-05-18 |
2012-06-07 |
Novartis Ag |
Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
|
|
KR100694508B1
(ko)
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
US8303955B2
(en)
|
2005-05-26 |
2012-11-06 |
Seattle Genetics, Inc. |
Humanized anti-CD40 antibodies and their methods of use
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
WO2007053661A2
(en)
|
2005-11-01 |
2007-05-10 |
Novartis Ag |
Uses of anti-cd40 antibodies
|
|
ES2400660T3
(es)
|
2005-11-01 |
2013-04-11 |
Novartis Ag |
Usos de anticuerpos anti-CD40
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
WO2007067991A2
(en)
|
2005-12-08 |
2007-06-14 |
Medarex, Inc. |
Human monoclonal antibodies to o8e
|
|
US20090304687A1
(en)
|
2005-12-09 |
2009-12-10 |
Seattle Genetics , Inc. |
Methods of using cd40 binding agents
|
|
BRPI0620264A2
(pt)
|
2005-12-22 |
2011-11-08 |
Prolexys Pharmaceuticals Inc |
quinazolonas aril-substituìdas e sua utilização
|
|
US20090170834A1
(en)
|
2005-12-22 |
2009-07-02 |
Prolexys Pharmaceuticals, Inc. |
Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
|
|
US20110008368A1
(en)
|
2006-01-13 |
2011-01-13 |
Board Of Regents, The University Of Texas System |
Methods of modulating the ox40 receptor to treat cancer
|
|
AR060487A1
(es)
|
2006-04-21 |
2008-06-18 |
Xoma Technology Ltd |
Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
|
|
EP1854810A1
(en)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
|
WO2007149476A2
(en)
|
2006-06-19 |
2007-12-27 |
Trustees Of Columbia University In The City Of New York |
Assays for non-apoptotic cell death and uses thereof
|
|
KR100745488B1
(ko)
|
2006-07-04 |
2007-08-02 |
학교법인 울산공업학원 |
항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
|
|
WO2008013987A2
(en)
|
2006-07-27 |
2008-01-31 |
Prolexys Pharmaceuticals, Inc. |
N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
EP2097447A4
(en)
|
2006-11-15 |
2010-12-29 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
|
|
CN105037549B
(zh)
|
2007-01-11 |
2018-09-28 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
EP2125893A2
(en)
|
2007-01-23 |
2009-12-02 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
WO2008103470A2
(en)
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
US20100143245A1
(en)
|
2007-03-22 |
2010-06-10 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8h9
|
|
AU2008247382B2
(en)
|
2007-05-07 |
2014-06-05 |
Medimmune, Llc |
Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
EP2152258B1
(en)
|
2007-05-10 |
2016-05-04 |
Avalon Pharmaceuticals |
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
|
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
WO2009002553A1
(en)
*
|
2007-06-25 |
2008-12-31 |
Prolexys Pharmaceuticals, Inc. |
Methods of treating multiple myeloma and resistant cancers
|
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
MX2010005099A
(es)
|
2007-11-09 |
2010-05-27 |
Novartis Ag |
Usos de anticuerpos anti-cd40.
|
|
CL2008003526A1
(es)
|
2007-11-30 |
2010-01-11 |
Medarex Inc |
Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
|
|
WO2009073809A2
(en)
|
2007-12-04 |
2009-06-11 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
CA2712989C
(en)
|
2008-01-23 |
2015-10-27 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
EP2279003A4
(en)
|
2008-05-01 |
2013-04-03 |
Gtc Biotherapeutics Inc |
ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
|
|
CA2729567C
(en)
|
2008-06-30 |
2018-04-24 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-cd27 antibody
|
|
ES2685823T3
(es)
|
2008-07-16 |
2018-10-11 |
Baylor Research Institute |
Anticuerpos antagonistas anti-CD40
|
|
US20110097339A1
(en)
|
2008-07-18 |
2011-04-28 |
Domantis Limited |
Compositions monovalent for CD28 binding and methods of use
|
|
PE20110385A1
(es)
|
2008-07-18 |
2011-06-22 |
Bristol Myers Squibb Co |
Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
|
|
AR073459A1
(es)
|
2008-07-18 |
2010-11-10 |
Domantis Ltd |
Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
EP2367553B1
(en)
|
2008-12-05 |
2017-05-03 |
Novo Nordisk A/S |
Combination therapy to enhance nk cell mediated cytotoxicity
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010082912A1
(en)
|
2009-01-15 |
2010-07-22 |
Avalon Pharmaceuticals |
Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents
|
|
NZ594315A
(en)
|
2009-02-17 |
2013-05-31 |
Ucb Pharma Sa |
Antibody molecules having specificity for human ox40
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
AU2010222942B2
(en)
|
2009-03-10 |
2013-01-10 |
Baylor Research Institute |
Anti-CD40 antibodies and uses thereof
|
|
CN102770457A
(zh)
|
2009-03-10 |
2012-11-07 |
贝勒研究院 |
靶向抗原呈递细胞的疫苗
|
|
JP5748653B2
(ja)
|
2009-04-10 |
2015-07-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
|
|
ES2829423T3
(es)
|
2009-04-20 |
2021-05-31 |
Kyowa Kirin Co Ltd |
Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
|
|
WO2010132389A2
(en)
|
2009-05-14 |
2010-11-18 |
University Of Maryland, Baltimore |
Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
|
|
BR112012007875A2
(pt)
|
2009-07-31 |
2016-11-22 |
Medarex Inc |
anticorpos totalmente humanos para btla
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
WO2011031063A2
(ko)
|
2009-09-09 |
2011-03-17 |
울산대학교 산학협력단 |
항 4-1bb 항체를 포함하는 대사성 질환의 예방 또는 치료용 조성물
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
SG181533A1
(en)
|
2009-12-07 |
2012-07-30 |
Univ Leland Stanford Junior |
Methods for enhancing anti-tumor antibody therapy
|
|
KR101773216B1
(ko)
|
2009-12-29 |
2017-08-31 |
교와 핫꼬 기린 가부시키가이샤 |
항 ｃｄ27 항체
|
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
|
KR20110085038A
(ko)
|
2010-01-19 |
2011-07-27 |
울산대학교 산학협력단 |
항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
|
|
LT2536764T
(lt)
|
2010-02-18 |
2018-10-25 |
Ose Immunotherapeutics |
Anti-cd28 humanizuoti antikūnai
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
HUE049849T2
(hu)
|
2010-03-31 |
2020-10-28 |
Boehringer Ingelheim Int |
Anti-CD40 antitestek
|
|
EP2560994B1
(en)
|
2010-04-08 |
2016-10-12 |
JN Biosciences LLC |
Antibodies to cd122
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
AU2011262758B8
(en)
|
2010-06-11 |
2014-09-04 |
Kyowa Kirin Co., Ltd. |
Anti-tim-3 antibody
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
CA2809089C
(en)
|
2010-08-23 |
2018-12-18 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
EP2643350A4
(en)
|
2010-11-22 |
2015-01-07 |
Innate Pharma Sa |
TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
|
|
WO2012075111A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
|
|
WO2012087928A2
(en)
|
2010-12-20 |
2012-06-28 |
The Rockefeller University |
Modulating agonistic tnfr antibodies
|
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
|
JP5458188B2
(ja)
|
2011-02-17 |
2014-04-02 |
協和発酵キリン株式会社 |
抗ｃｄ４０抗体の高濃度製剤
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
TR201909840T4
(tr)
|
2011-03-11 |
2019-07-22 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antikorları ve kullanımları.
|
|
EP3147297B1
(en)
|
2011-03-31 |
2018-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies directed against icos and uses thereof
|
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
HUE038848T2
(hu)
|
2011-04-21 |
2018-11-28 |
Bristol Myers Squibb Co |
CD40-antagonista antitest polipeptidek
|
|
WO2012147713A1
(ja)
|
2011-04-25 |
2012-11-01 |
第一三共株式会社 |
抗ｂ７－ｈ３抗体
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
ES2765874T3
(es)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
WO2013008171A1
(en)
|
2011-07-11 |
2013-01-17 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to ox40 and their uses
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
CA2845810C
(en)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
NZ629697A
(en)
|
2012-03-15 |
2017-01-27 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods and uses
|
|
WO2013152039A1
(en)
|
2012-04-02 |
2013-10-10 |
The Trustees Of Columbia University In The City Of New York |
Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
|
|
US9695133B2
(en)
|
2012-07-13 |
2017-07-04 |
The Trustees Of Columbia University In The City Of New York |
Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
|
|
US9268936B2
(en)
|
2012-07-27 |
2016-02-23 |
Mandiant, Llc |
Physical memory forensics system and method
|
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
ES2773710T3
(es)
|
2012-10-11 |
2020-07-14 |
Daiichi Sankyo Co Ltd |
Enlazadores para conjugados de anticuerpo - fármaco
|
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
|
|
EP2912063A1
(en)
|
2012-10-23 |
2015-09-02 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
|
|
JPWO2014065402A1
(ja)
|
2012-10-26 |
2016-09-08 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
JP2016011258A
(ja)
|
2012-10-26 |
2016-01-21 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
KR102270618B1
(ko)
|
2012-10-30 |
2021-06-30 |
아펙시젠, 인코포레이티드 |
항-cd40 항체 및 사용 방법
|
|
CA2894879A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
WO2014129168A1
(ja)
|
2013-02-20 |
2014-08-28 |
日本電気株式会社 |
空間安定装置、空間安定方法、及び空間安定プログラム記憶媒体
|
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及びイムノコンジュゲート
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
WO2014140374A2
(en)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Monovalent cd27 antibodies
|
|
US20140322236A1
(en)
|
2013-03-15 |
2014-10-30 |
Sdix, Llc |
Anti-human adora2a antibodies
|
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
US20160084839A1
(en)
|
2013-04-02 |
2016-03-24 |
Marisa Dolled-Filhart |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
|
BR112015029395A2
(pt)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
Anticorpos anti-b7-h5 e seus usos
|
|
WO2014194302A2
(en)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
SG11201509982UA
(https=)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
AU2014296887A1
(en)
|
2013-08-02 |
2016-01-28 |
Aduro Biotech Holdings, Europe B.V. |
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
WO2015051149A1
(en)
|
2013-10-04 |
2015-04-09 |
The Trustees Of Columbia University In The City Of New York |
Sorafenib analogs and uses thereof
|
|
ES2707057T3
(es)
|
2013-11-06 |
2019-04-02 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
|
|
EP3384908B1
(en)
|
2013-12-02 |
2020-09-30 |
The Trustees of Columbia University in the City of New York |
Modulating ferroptosis and treating excitotoxic disorders
|
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
CN105611944A
(zh)
|
2013-12-20 |
2016-05-25 |
豪夫迈·罗氏有限公司 |
抗ang2抗体和cd40激动剂的组合疗法
|
|
EP3094332B1
(en)
|
2014-01-15 |
2018-09-12 |
The Trustees of Columbia University in the City of New York |
Carbonyl erastin analogs and their use
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
EP3113796A1
(en)
|
2014-03-07 |
2017-01-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
|
CN106413751A
(zh)
|
2014-05-21 |
2017-02-15 |
辉瑞大药厂 |
用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
|
|
SI3148579T1
(sl)
|
2014-05-28 |
2021-07-30 |
Agenus Inc. |
Proti GITR antitelesa in postopki z njihovo uporabo
|
|
EP3149040A1
(en)
|
2014-05-29 |
2017-04-05 |
Spring Bioscience Corporation |
Anti-b7-h3 antibodies and diagnostic uses thereof
|
|
MA40074A
(fr)
|
2014-05-30 |
2015-12-03 |
Univ Columbia |
Composés liant ras multivalents
|
|
PE20170441A1
(es)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
|
|
WO2015188047A1
(en)
|
2014-06-06 |
2015-12-10 |
University Of Maryland, Baltimore |
ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
|
|
EP3157563A1
(en)
|
2014-06-23 |
2017-04-26 |
TheraMAB LLC |
Compositions and methods for safe and effective immunotherapy
|
|
CN106659852A
(zh)
|
2014-07-09 |
2017-05-10 |
诺和诺德股份有限公司 |
机动化药物输送装置
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
CA2957146A1
(en)
|
2014-08-12 |
2016-02-18 |
Alligator Bioscience Ab |
Combination therapies with anti cd40 antibodies
|
|
WO2016023875A1
(en)
|
2014-08-14 |
2016-02-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
|
|
WO2016028810A1
(en)
|
2014-08-18 |
2016-02-25 |
Biogen Ma Inc. |
Anti-cd40 antibodies and uses thereof
|
|
EP3183269A2
(en)
|
2014-08-22 |
2017-06-28 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
KR102485788B1
(ko)
|
2014-08-27 |
2023-01-09 |
메모리얼 슬로안 케터링 캔서 센터 |
항체, 조성물 및 용도
|
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
WO2016040724A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
RU2017115315A
(ru)
|
2014-10-03 |
2018-11-08 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
KR20170075778A
(ko)
|
2014-10-27 |
2017-07-03 |
에이전시 포 사이언스, 테크놀로지 앤드 리서치 |
항-tim-3 항체
|
|
US11639384B2
(en)
|
2014-10-28 |
2023-05-02 |
University Children's Hospital Tübingen |
Treatment of pediatric BCP-ALL patients with an anti-KIR antibody
|
|
BR112017008959A2
(pt)
|
2014-10-29 |
2018-01-16 |
Seattle Genetics, Inc. |
método para tratamento de uma doença.
|
|
US10626176B2
(en)
|
2014-10-31 |
2020-04-21 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind B7-H4
|
|
SI3215532T1
(sl)
|
2014-11-06 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Protitelesa proti TIM3 in postopki uporabe
|
|
JP6800853B2
(ja)
|
2014-12-11 |
2020-12-16 |
ピエール、ファーブル、メディカマン |
抗ｃ１０ｏｒｆ５４抗体およびその使用
|
|
US9963509B2
(en)
|
2014-12-23 |
2018-05-08 |
Full Spectrum Genetics, Inc. |
Anti-B7H3 binding compounds and uses thereof
|
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
WO2017058716A1
(en)
|
2015-09-28 |
2017-04-06 |
Vivace Therapeutics, Inc. |
Tricyclic compounds
|
|
US20190008961A1
(en)
|
2016-01-07 |
2019-01-10 |
The Broad Institute, Inc. |
Compounds and methods for increasing tumor infiltration by immune cells
|
|
WO2018118711A1
(en)
|
2016-12-19 |
2018-06-28 |
The Trustees Of Columbia University In The City Of New York |
Small molecule ferroptosis inducers
|
|
CN108409737B
(zh)
|
2017-02-10 |
2020-07-03 |
华东理工大学 |
4-甲氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其应用
|
|
EP3630089A4
(en)
|
2017-05-24 |
2021-06-09 |
Ferro Therapeutics, Inc. |
PROCEDURE FOR CANCER THERAPY
|
|
EP3645739A4
(en)
*
|
2017-06-28 |
2021-07-14 |
The Regents of the University of California |
METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA
|
|
US20200397817A1
(en)
*
|
2017-11-30 |
2020-12-24 |
SHIEH, Darbin |
Method for predicting and modulating susceptibility of cancer cell to programmed cell death
|
|
US20200383943A1
(en)
*
|
2017-12-04 |
2020-12-10 |
Memorial Sloan Kettering Cancer Center |
Methods of cancer treatment via regulated ferroptosis
|
|
JP7348906B2
(ja)
|
2018-02-28 |
2023-09-21 |
フェロ セラピューティクス， インコーポレイテッド |
フェロトーシス誘導活性を有する化合物およびそれらの使用方法
|
|
US11040964B2
(en)
|
2019-02-27 |
2021-06-22 |
Ferro Therapeutics, Inc. |
Compounds and methods of use
|